

MAXONA Pharmaceuticals Closes on \$6,960,500 Series B Convertible Preferred Stock Offering



About the Offering

On December 23, 2024, MAXONA Pharmaceuticals Inc., ("MAXONA", "the Company") a clinical-stage biopharmaceutical company developing a non-opioid, non-NSAID analgesic for the treatment of pain in the United States, closed on a Private Placement of \$6,960,500 of its Series B Convertible Preferred Stock Offering. The offering included participation from new and existing Institutional, High Net Worth and Family Office Investors.

Brookline Capital Markets, a division of Arcadia Securities, LLC, served as exclusive placement agent for this offering.

Brookline previously raised MAXONA's initial funding of \$10,000,000 in the Company's Series A Convertible Preferred Stock offering, which closed in October 2021.

About MAXONA Pharmaceuticals

MAXONA Pharmaceuticals, headquartered in Malvern, PA, is a privately held clinical-stage pharmaceutical company committed to developing the next generation of therapies to help patients maximize life. The company is distinguished by its strong and diversified leadership team with expertise in neuroscience, drug development, drug formulation and delivery technology, clinical trial design and pharmacology to develop patient-centric therapies that are safe, efficacious, clinically proven and trusted by physicians and their patients. The company's initial focus is on advancing MAX-001 as a safe and highly effective non-opioid option for the treatment of acute and chronic pain.

Brookline Capital Markets' Suite of Finance Solutions

At Brookline, we pride ourselves on our ability to partner with private corporate clients from inception to IPO. We have established a market-leading platform in the pre-IPO healthcare investment banking arena. Our premier public capital markets franchise dedicates itself to raising capital in the IPO, follow-on, PIPE and convertible markets, as well as to providing capital markets advisory services to its roster of clients.

We stand ready to provide value-added investment banking advice, analysis, and execution for our healthcare corporate clients at any point of clinical development or financial maturity.

Brookline's public capital markets services include:

- **Equity Underwriting:** Initial Public Offerings, Follow-On Offerings, Confidentially Marketed Public Offerings ("CMPOs"), and Registered Direct Offerings ("RDs")
- **Private Placements:** Private Investment in Public Equity Financings ("PIPEs")
- **Advisory:** IPO Advisory, Capital Markets Advisory, and Strategic Advisory

** Obtained from sources believed to be reliable including: FactSet, SEC filings and the Company website*

Legal Disclaimer

This publication is prepared by the Equities Department of Brookline Capital Markets, a division of Arcadia Securities, LLC ("Brookline") and is not the product of Brookline's Equity Research Department. This publication is provided for informational purposes only, and it is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This publication contains market prices, statistical data and other information (collectively, "Information") from third-party sources believed by Brookline to be reliable. Such Information, however, is neither all-inclusive nor guaranteed or warranted by Brookline to be accurate or complete, and it should not be relied upon as such. Such Information is also subject to change, without notice, and Brookline does not undertake to advise recipients of this publication of changes, if any. Past performance is not a guarantee of future results, and Brookline makes no representation or warranty, express or implied, in respect of future performance of any security (or any grouping of securities) mentioned in this publication. The price of the securities mentioned in this publication and the income they produce may fluctuate and/or be adversely affected by, among other things, exchange rates and/or market conditions, and investors may realize losses on investments in such securities, including the loss of investment principal. Brookline accepts no liability for any loss arising from the use of information contained in this publication, except to the extent that liability may arise under specific statutes or regulations applicable to Brookline.

In the course of its regular business, Brookline may be long or short in the securities mentioned in this publication and may make purchases and/or sales of them or options to purchase or sell them from time to time in the open market, as a market maker or otherwise, including purchases from or sales to customers on a principal basis. In addition, Brookline may perform or seek to perform investment banking services for the issuers of the securities mentioned in this publication in the next three months and may have received compensation for such services within the last 12 months.

Member FINRA and SIPC

© 2025 Brookline Capital Markets. All rights reserved. Unauthorized use, distribution, duplication or disclosure without the prior written permission of Brookline in each instance is prohibited.